Data for: "Seasonal Malaria Chemoprevention combined with Community Case Management of malaria in children under 10 years of age, over 5 months, in southern Senegal: a cluster-randomized trial"

1017 46 6449 3 27424 document 6449 Codebook.html text/html e9f5f96ea2205718d8aed8a4c19235fd3c4c21767788cc68a8d34f91fdb4eea0 SHA256 3571 2019-02-12 11:10:33 https://datacompass.lshtm.ac.uk/id/eprint/1017/1/Codebook.html 1017 1 2 text/html Text en public cc_by

Codebook.html

documentation indefinite Codebook for Seasonal Malaria Chemoprevention dataset 17202 1 95528 document 17202 indexcodes.txt text/plain 692a41c12d9904b99a3ef37ccfd4c13ce397f59055ac908cc8f8fc5e4d708e4b SHA256 802 2025-02-07 10:24:29 https://datacompass.lshtm.ac.uk/id/eprint/1017/3/indexcodes.txt 1017 3 3 text/plain en public

indexcodes.txt

http://eprints.org/relation/isVersionOf https://datacompass.lshtm.ac.uk/id/document/6449 http://eprints.org/relation/isVolatileVersionOf https://datacompass.lshtm.ac.uk/id/document/6449 http://eprints.org/relation/isIndexCodesVersionOf https://datacompass.lshtm.ac.uk/id/document/6449 indefinite Generate index codes conversion from Text to indexcodes 17985 3 98504 document 17985 SMC-dataset.zip application/zip 0d1302400b93db9208a902ae0979b813856139c09f45d54810cbf89e09ce5e01 SHA256 248 2025-06-02 14:21:27 https://datacompass.lshtm.ac.uk/id/eprint/1017/4/SMC-dataset.zip 1017 4 1 application/zip Dataset en staffonly datasharingagreement

SMC-dataset.zip

data indefinite Seasonal Malaria Chemoprevention datasets: These data are restricted. Interested parties are welcome to get in touch to discuss how to obtain access archive 64 disk0/00/00/10/17 2019-02-12 11:25:32 2026-02-10 16:18:48 2019-02-12 11:25:32 data_collection show NDiaye Jean Louis FALSE Milligan Paul 0000-0003-3430-3395 TRUE f89e771702e1b23788797da3139d98d0 Universite Cheikh Anta Diop, Dakar, Senegal London School of Hygiene & Tropical Medicine, London, United Kingdom Data for: "Seasonal Malaria Chemoprevention combined with Community Case Management of malaria in children under 10 years of age, over 5 months, in southern Senegal: a cluster-randomized trial" EPID Seasonal Malaria Chemoprevention Sulfadoxine-pyrimethamine Amodiaquine This data is restricted, but interested parties are welcome to contact the corresponding author via the request form to discuss the analysis performed. Seasonal Malaria Chemoprevention (SMC), is recommended in the Sahel region of Africa for children under 5 years of age, for up to 4 months of the year. It may be appropriate to include older children, and to provide protection for more than 4 months. We evaluated the effectiveness of SMC using sulfadoxine-pyrimethamine plus amodiaquine over 5 months in children under 10 years of age, in Saraya district in southern Senegal in 2011. 24 villages, including 2301 children 3-59 months old and 2245 aged 5-9 years, were randomized to receive SMC with community case management (CCM), or CCM alone. In all villages, community health workers (CHWs) were trained to treat malaria cases with artemisinin combination therapy after testing with a rapid diagnostic test (RDT). In SMC villages, CHWs administered SMC to children aged 3 months to 9 years, once a month for 5 months. Children were followed from July to December. The primary outcome was malaria (fever or history of fever with a positive RDT). The prevalence of anaemia and parasitaemia was measured in a survey at the end of the transmission season. Molecular markers associated with resistance to SMC drugs were analysed in samples from incident malaria cases, and from children with parasitaemia in the survey. 2019-01-30 completed London School of Hygiene & Tropical Medicine 10.17037/DATA.00001017 Dataset London School of Hygiene & Tropical Medicine, London, United Kingdom XMAL SelfAdministeredQuestionnaire.FixedForm.Paper 2011-07-27 2011-12-31 TRUE Seasonal Malaria Chemoprevention (SMC), is recommended in the Sahel region of Africa for children under 5 years of age, for up to 4 months of the year. It may be appropriate to include older children, and to provide protection for more than 4 months. We evaluated the effectiveness of SMC using sulfadoxine-pyrimethamine plus amodiaquine over 5 months in children under 10 years of age, in Saraya district in southern Senegal in 2011. 24 villages, including 2301 children 3-59 months old and 2245 aged 5-9 years, were randomized to receive SMC with community case management (CCM), or CCM alone. In all villages, community health workers (CHWs) were trained to treat malaria cases with artemisinin combination therapy after testing with a rapid diagnostic test (RDT). In SMC villages, CHWs administered SMC to children aged 3 months to 9 years, once a month for 5 months. Children were followed from July to December. The primary outcome was malaria (fever or history of fever with a positive RDT). The prevalence of anaemia and parasitaemia was measured in a survey at the end of the transmission season. Molecular markers associated with resistance to SMC drugs were analysed in samples from incident malaria cases, and from children with parasitaemia in the survey. LF-LFZ RN UXC-UXU restricted London, United Kingdom European and Developing Countries Clinical Trials Partnership Dataset Quantitative Senegal 12.9874 -11.5556 12.7263 -11.9607 en European and Developing Countries Clinical Trials Partnership http://dx.doi.org/10.13039/501100001713 European and Developing Countries Clinical Trials Partnership 2019-01-30